'In that moment, that was everything to me': Patient describes joy of regaining vision in 1 eye after new stem cell therapy
When you buy through links on our articles, Future and its syndication partners may earn a commission.
On Independence Day 2020, Nick Kharufeh was enjoying a fireworks display on the street near his aunt's house in California.
Then, within a split second, the fun stopped.
A wayward firework meandered off course and exploded on the ground near Kharufeh, and bits of the explosive struck the cornea of his left eye. The accident left Kharufeh — who was 23 years old, and six years into training to be a commercial pilot at the time — completely blind in one eye.
"My dad was right outside [the house] and it was dark out, so he couldn't fully tell what had happened," Kharufeh told Live Science. "And I was like, 'I feel like I can't see out of my left eye.'"
Related: Gene-therapy drops restore teen's vision after genetic disease left his eyes clouded with scars
At the hospital, doctors initially feared that Kharufeh's eye had been completely destroyed and would need to be taken out. However, after cleaning the debris from his eye, a specialist saw that aside from his cornea, the rest of Kharufeh's eye remained intact.
What followed was months of treatments, involving waking up multiple times in the night to apply medicated eye drops, taking drugs to manage the pain, and undergoing a couple of surgeries, which included cleaning up the remaining debris and an unsuccessful attempt at reconstructing his eyelid.
"It was a rough few months," Kharufeh said. "I didn't leave the house, I didn't tell anybody what happened because I was kind of embarrassed about it — because your eyes are the window to your soul, so I felt like my identity was just gone."
Later that year, Kharufeh's mom told him about an advertisement she'd seen from the Mass Eye and Ear, a Harvard teaching hospital in Boston, Massachusetts. The hospital was seeking volunteers to participate in a clinical trial of a new stem cell therapy for patients with irreversible corneal damage.
The experimental therapy — called "cultivated autologous limbal epithelial cell transplantation" (CALEC) — works by taking stem cells from a patient's healthy eye, growing them into sheets of cells in the lab and then transplanting them into the damaged eye. Once implanted, these new sheets of cells form a surface on which normal tissue can grow back.
Kharufeh decided to make the move to Boston with his mom to take part in the trial, which was starting the following January in 2021.
"At first I was hesitant because they had to do surgery on my good eye, so I was really nervous," Kharufeh said.
But then, immediately after the first of two transplants, Kharufeh saw positive results.
He remembers the moment when he walked into his Airbnb in Massachusetts and could see the bright blue color of his comforter. At that time, he was about eight months out from his firework injury.
Image 1 of 2
Image 2 of 2
Nick's eye approximately two years after receiving his first stem cell transplant at Mass Eye and Ear.
"I'll never forget [that moment]," Kharufeh said. "And it sounds so little. It's just like, 'Okay, a little blue comforter.' But in that moment that was everything to me, and I literally cried for so long."
Prior to Kharufeh receiving the new CALEC therapy, the treatment had initially been tested in a small clinical trial of just four patients with corneal damage. That trial, whose results were shared in 2018, marked the first-ever test of a stem cell therapy for the eyes in the U.S., the research team said at the time.
After the small trial demonstrated the therapy's safety and efficacy, the team conducted a larger trial with 15 patients, one of whom was Kharufeh. The findings of the larger trial were published March 4 in the journal Nature Communications, and overall, the treatment was found to be effective at repairing blinding damage to the cornea in 93% of the patients involved. Follow-up trials are still to come and could ensure the treatment's official approval.
Now, at age 28 and five years out from his injury, Kharufeh still lives in Boston where he works in sales for a travel company. The vision from his left eye is not perfect, but he says that the injury doesn't cause him issues during his everyday life. For instance, if he were to cover his right eye with his hand, he would still be able to locate objects and navigate himself around.
RELATED STORIES
—A dozen squirming fly larvae cause man's 'itchy eye'
—Blind people could 'see' letters that scientists drew on their brains with electricity
—Nerve damage in cornea could be sign of 'long COVID,' study hints
In April, he intends to run the Boston Marathon to help raise money for Mass Eye and Ear.
"I think it's given me a whole new life," Kharufeh said of the stem-cell therapy. "Now it's the point where I can actually feel normal."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
Does the color purple really exist?
When you buy through links on our articles, Future and its syndication partners may earn a commission. The world is awash with the color purple — lavender flowers, amethyst gemstones, plums, eggplants and purple emperor butterflies. But if you look closely at the visible-light portion of the electromagnetic spectrum, you'll notice that purple (which is different from bluish hues of violet and indigo) is absent. That's because purple may be made up by our brains; It exists only because of how the brain processes color. So does that mean purple doesn't really exist? Not necessarily. The answer lies within the mind-boggling way that our brains perceive and combine different wavelengths on the visible light spectrum. "I would actually say that none of color actually exists," said Zab Johnson, an executive director and senior fellow at the Wharton Neuroscience Initiative at the University of Pennsylvania. "It's all the process of our neural machinery, and that's sort of both the beauty and the complexity of it all at the same time." Sign up for our newsletter Sign up for our weekly Life's Little Mysteries newsletter to get the latest mysteries before they appear online. All color begins with light. When radiation from the sun hits Earth, a range of wavelengths are present. There are long wavelengths, like infrared rays and radio waves, and shorter, high-energy wavelengths, like X-rays and ultraviolet rays, which are damaging to our bodies, Johnson told Live Science. Toward the middle of the electromagnetic spectrum lies visible light — the light our brains can see — which represents only about 0.0035% of the electromagnetic spectrum. This is what we perceive as the colors of the rainbow. On one end of the spectrum are longer wavelengths, which we perceive as red, and on the other are shorter wavelengths, which we perceive as indigo and violet. Our perception of color involves specialized receptors at the back of our eyeballs, called cones, that detect visible light. Human eyes have three types of cones: long wave, mid wave and short wave. Each is sensitive to particular wavelengths. Long-wavelength cones take in information on reddish light, mid-wavelength cones specialize in green, and short-wavelength cones detect blue. Related: What color is the universe? When light hits our eyeballs, these three receptors take in information about the light and their respective wavelengths and send electrical signals to the brain. The brain then takes that information and makes an average deduction of what it's seeing. "Our machinery is sort of doing this complex sort of calculation of these three different ratios all the time," which forms our perception of color, Johnson said. For example, if long-wavelength and mid-wavelength cones are triggered, the brain infers that we're seeing orange or yellow. If mid-wavelength and short-wavelength cones are activated, the brain will make a conclusion of teal. So what about purple? When short-wavelength (blue) and long-wavelength (red) cones are stimulated, your brain "makes something that's actually not out there in the world," Johnson said. Red and blue are on opposite ends of the visible spectrum: When the brain encounters these wavelengths, it ends up bending this linear visible spectrum into a circle. In other words, it brings red and blue together to make purple and magenta, even though that's not what light is really doing. As a result, purple and magenta are known as "nonspectral" colors, because they don't really exist as actual electromagnetic radiation. Nonspectral colors like purple are made of two wavelengths of light. In contrast, spectral colors — red, orange, yellow, green, blue, indigo and, importantly, violet and indigo — are made of just one wavelength. RELATED MYSTERIES —Why is the sky blue? —Why do we see colors that aren't there? —What would colors look like on other planets? Regardless of its physical existence, purple has captivated people for millennia, noted Narayan Khandekar, director of the Straus Center for Conservation and Technical Studies at Harvard Art Museums. For example, ancient Phoenicians ground up sea snails to make a color known as Tyrian purple, which was reserved for royal or ceremonial robes. Today, purple is still often associated with wealth, power and even magic. "So that connection still exists, even though there are other versions of purple available now," he told Live Science. So, whether manufactured in our minds or made from ground-up shellfish, purple is unique and deserves closer look. "It doesn't really exist in nature. And so when you can create it, it has this extra value," Johnson said. "Now purple is even more special."
Yahoo
18 hours ago
- Yahoo
Scientists Intrigued by Conical Skull Found in Ancient Burial Ground
Archaeologists in Iran have discovered an ancient cone-shaped skull that is believed to have belonged to a teen girl — and there are signs of tragedy in her bones. As Live Science reports, the skull, which was found in a prehistoric burial ground known as Chega Sofla without its corresponding skeleton, shows signs not only of intentional modification, but also possibly fatal blunt force trauma. Dated to roughly 6,200 years old, the strange cone shape of the skull appears to be the product of a practice archaeologists today call artificial cranial modification, a process similar to foot-binding in which the soft skulls of children are bandaged to deliberately deform them. Found across cultures and millennia, this type of body modification has been undertaken for various reasons, including to denote social status or adhere to beauty standards, as evidenced by it more often being seen in girls than boys. Though it's still occasionally practiced today, the practice sometimes referred to as "skull elongation" was far more common in prehistoric times. The girl with the conical skull in this study, for instance, was believed to have lived in the fifth millennium BCE. Aside from the cone-shaped cranium of the young woman, who was believed to be younger than the age of 20, archaeologists Mahdi Alirezazadeh and Hamed Vahdati Nasab of the Tarbiat Modares University in Tehran — who also authored a study about their discovery that was recently published in the International Journal of Osteoarcheology — also found a long, unhealed fracture on the back of the skull that likely killed her. "We know this woman experienced the fracture in the final moments of her life," Alirezazadeh told Live Science, "but we don't have any direct evidence to say that someone intentionally struck her." Though it's unclear whether the ancient teen in question was intentionally killed or died by accident, the researchers believe that the modified shape of her skull likely made it weaker and more susceptible to trauma than a conventional cranium. Along with pointing out that an unmodified fractured skull was found alongside the conical skull in the portion of Chega Sofia where they were working, Alirezazadeh also noted that whatever killed the latter "was so severe that it would have fractured a normal, unmodified skull as well." More on head science: Scientists Want You to Ink an Electronic Tattoo On Your Forehead So Your Boss Can Detect Your Mental State
Yahoo
a day ago
- Yahoo
There's a new blood test for Alzheimer's. Here's everything you need to know.
When you buy through links on our articles, Future and its syndication partners may earn a commission. The U.S. Food and Drug Administration (FDA) recently cleared a blood test that detects signs of Alzheimer's disease in the brain, according to multiple studies. This is the first-ever blood test available for this common form of dementia. Here's how the new blood test works and why it could be useful to patients. Alzheimer's disease is on the rise, in part because the age group most prone to dementia is growing larger. In the U.S., an estimated 7.2 million Americans ages 65 and older are living with Alzheimer's dementia in 2025. The percentage of affected people increases with age: About 5% of people ages 65 to 74 have Alzheimer's, compared with more than 33% of people ages 85 and older. At the point when a doctor has verified that a patient has cognitive decline, the blood test can be used in place of standard tests to see if they likely have Alzheimer's. Previously, gold-standard methods of diagnosing Alzheimer's have been more invasive and expensive, involving positron emission tomography (PET) scans, which use radioactive substances; and lumbar punctures, (also called spinal taps) during which a clinician uses a needle to sample spinal fluid from the low back. Clinicians also sometimes use MRIs or CT scans to rule out other causes of cognitive decline. The new test measures the ratio of two proteins in human blood, and this ratio correlates with the presence or absence of amyloid plaques, a primary sign of Alzheimer's found in the brain. For people experiencing memory lapses that might be due to Alzheimer's, the first step is to see their primary care physician (PCP), who should do a cognitive test. If there are signs of cognitive impairment, the patient would then be referred to a neurologist for an in-depth evaluation. Both dementia specialists and PCPs will be able to order this blood test to help with diagnosis, said Dr. Gregg Day, a neurologist with the Mayo Clinic in Jacksonville, Florida; Day led a study of the blood test published in June in the Journal of the Alzheimer's Association. A study published in 2024 in JAMA found that whether the test was ordered by a PCP or specialist, it was equally accurate at confirming suspected Alzheimer's diagnoses. PCPs could use the test results to decide whether to refer patients to a specialist, who could prescribe treatments such as lecanemab or donanemab, Day said. Or the PCP could personally prescribe a medicine like donepezil, which can help improve mental function in Alzheimer's. With FDA clearance, Medicare and private health insurance providers alike are expected to cover the new blood test, Day said. The test — called the "Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio" — is intended for people ages 55 and older who show signs and symptoms of cognitive decline that have been confirmed by a clinician. The test is designed for the early detection of amyloid plaques associated with Alzheimer's disease. (Amyloid plaques are unusual clumps found between brain cells and made up of a type of protein called beta-amyloid.) Related: Man nearly guaranteed to get early Alzheimer's is still disease-free in his 70s — how? Early detection is important, said Dr. Sayad Ausim Azizi, clinical chief of behavioral neurology and memory disorders at the Yale School of Medicine. That's because the Alzheimer's brain is like a rusty engine — the plaque is like rust settling onto the engine, interfering with the wheels' ability to turn, Azizi told Live Science. There are FDA-approved treatments that act like oil, helping the wheels to turn, but the medication does not remove the rust itself, he said. Available therapies can slow down the degradation of the brain by about 30% to 40%, studies show, so the patient can retain function for longer. "If you're driving now and living independently and you don't take the medicine, it's likely in five years you won't be able to do all these things," Azizi said, providing a hypothetical example. "If you take the medicine, the five years are extended to eight." If adopted as intended, the new blood test could help more people access these treatments sooner. The test is not recommended for the purposes of screening the general population. It is intended only for people who have been found by a doctor to exhibit signs of Alzheimer's disease, Day and Azizi emphasized. Some amount of amyloid is present in the brain during healthy aging, so its presence doesn't guarantee someone will later have Alzheimer's. If the test detects signs of amyloid plaques 20 years before any cognitive symptoms surface, Azizi explained, it would not make sense to treat the patient at that time. "The treatments are not 100% benign," he added. To receive lecanemab, for example, patients must be able to receive an infusion every two weeks at first and every four weeks later on; donanemab is given every four weeks. Both medications can come with infusion-related reactions, such as headache, nausea and vomiting. Rarely, the treatment donanemab can cause life-threatening allergic reactions, and both lecanemab and donanemab have been tied to rare cases of brain swelling or bleeding in the brain. These latter side effects are related to "amyloid-related imaging abnormalities," which are structural abnormalities that appear on brain scans. The new test can give false positives, meaning a person can potentially test positive when they don't actually have Alzheimer's. That's because the signs of amyloid that the tests look for can be tied to other conditions. For instance, amyloid buildup in the brain could be a sign the kidneys are not functioning optimally, Day said, so he recommends also doing a blood test for kidney function when ordering the Alzheimer's blood test. The Mayo Clinic study included about 510 people, 246 of whom showed cognitive decline; the blood test confirmed 95% of those with cognitive symptoms had Alzheimer's. About 5.3% of cases showed a false negative on the blood test, while 17.6% of cases gave a false positive, Day said. Most of the false-positive patients still had Alzheimer's-like changes in their brains, but their symptoms were ultimately attributed to other diseases, such as Lewy body dementia, Day said. The Mayo study found that the blood test helped doctors distinguish Alzheimer's from these other forms of dementia. As is true of many clinical trials, evaluations of the test have primarily included populations that are healthier than average, Day said. These individuals are not only healthier at baseline, but are more likely to have health insurance and be white and non-Hispanic. So when the blood test is used in a broader population, there may be people with sleep apnea or kidney disease who test positive despite not having Alzheimer's, Day said. Some people with these health problems may also experience memory issues or cognitive impairment that's not caused by Alzheimer's disease. If the blood test points to amyloid buildup, doctors could order additional tests and ask patients about their sleep to help rule out these other possibilities. RELATED STORIES —Could vaccines prevent and treat Alzheimer's disease? —Study unravels whole new layer of Alzheimer's disease —Alzheimer's comes in at least 5 distinct forms, study reveals The test will give researchers a more precise idea of how a patient's clinical symptoms relate to the findings on their blood test, Azizi said. "It's a great way of using a biomarker [measurable sign of disease] in the blood to make an earlier diagnosis to give a drug" to slow disease progression, he said. Azizi added that this blood test could help track whether a treatment for Alzheimer's disease is working, which would be useful both for patients receiving approved medicines and those in trials of new drugs. Looking forward, researchers will also be able to evaluate how well blood-based testing works in more diverse populations, Day noted. This article is for informational purposes only and is not meant to offer medical advice.
